The AUA annual meeting is a remarkable gathering of international thought leaders, practitioners, and industry. As in past years, last month's event in Anaheim provided attendees not only with a measure of urology's scientific progress but also a barometer for many of the issues and concerns facing urologists in the trenches. Here is a very brief look at some of the science and trends that drew applause and raised eyebrows during the scientific sessions, on the exhibit floor, and behind closed doors.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.